- Mycenax Biotech Inc. has signed a global License Agreement with Japan-based RIN Institute Inc. for access to its proprietary Val-Leu-Lys (VLK) linker technology.
- The deal enhances Mycenax’s capabilities to deliver differentiated antibody-drug conjugate (ADC) solutions within its global CDMO services.
Mycenax Biotech Inc., a biologics CDMO headquartered in Taiwan, has entered into a License Agreement with Japan’s RIN Institute Inc., granting Mycenax worldwide rights to use RIN’s Val-Leu-Lys (VLK) linker technology in its CDMO services.
RIN’s VLK linker has shown strong anti-tumour efficacy and high serum stability, supporting the development of next-generation antibody-drug conjugates (ADCs). The technology promotes cytotoxicity through two mechanisms—activity within the tumour microenvironment and enhanced ADC internalisation—enabling improved therapeutic outcomes.
According to Mycenax, the agreement expands its technical capabilities and strengthens its position in contract manufacturing of ADCs for global pharmaceutical partners.
“We are thrilled to finalise this agreement with RIN Institute, marking an important milestone in our mission to provide innovative and competitive ADC solutions.”
Pei-Jiun Chen, CEO and President of Mycenax.
This partnership builds upon a Letter of Intent signed on 7 April 2025, establishing the basis for continued collaboration between the two companies in advancing ADC innovation.
